Alchemia (ASX: ACL) has been granted patents for two of its family of the synthetic heparin oligosaccharides used in its fondaparinux synthesis production method.

Two of its other patent applications have been approved but not yet finalised.

The patents will grant legal protection to Alchemia's method of synthesising fondaparinux sodium up until the year 2022.

Alchemia, and its manufacturing partner Dr Reddy's, hope to go to market in 2009.

Fondaparinux is an anticoagulant medication,generally used subcutaneously daily, particularly in the treatment of deep-vain thrombosis and in those recovering from orthopaedic surgery.